AIM ImmunoTech Inc. (AIM) stock
AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.15+0.00 (+0.13%)
Close on Nov 12, 2026Market cap $4.52MP/E –Yield –
AIM ImmunoTech operating margin
Operating margin is operating income as a percentage of revenue.
AIM ImmunoTech's operating margin for the twelve months ending Sep 30, 2026 was -12800.0%. For fiscal 2025 it was -13254.5%, against -11630.6% the year before. The highest annual figure on record is -2612.4% in fiscal 2017.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -13254.5% | −1624.0 |
| FY2024 | Dec 31, 2024 | -11630.6% | +4169.4 |
| FY2023 | Dec 31, 2023 | -15800.0% | −1670.2 |
| FY2022 | Dec 31, 2022 | -14129.8% | −175.7 |
| FY2021 | Dec 31, 2021 | -13954.1% | −4658.4 |
| FY2020 | Dec 31, 2020 | -9295.7% | −407.8 |
| FY2019 | Dec 31, 2019 | -8887.9% | −5755.4 |
| FY2018 | Dec 31, 2018 | -3132.4% | −520.1 |
| FY2017 | Dec 31, 2017 | -2612.4% | +12392.0 |
| FY2016 | Dec 31, 2016 | -15004.3% | −2485.6 |
| FY2015 | Dec 31, 2015 | -12518.8% | −2823.9 |
| FY2014 | Dec 31, 2014 | -9694.9% | +1749.7 |
| FY2013 | Dec 31, 2013 | -11444.7% | −1895.4 |
| FY2012 | Dec 31, 2012 | -9549.3% | −670.4 |
| FY2011 | Dec 31, 2011 | -8878.9% | +3259.6 |
| FY2010 | Dec 31, 2010 | -12138.5% | −189.0 |
| FY2009 | Dec 31, 2009 | -11949.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -13440.9% | −4029.4 |
| Q2 FY2026 | Jun 30, 2026 | -13511.5% | −2927.5 |
| Q1 FY2026 | Mar 31, 2026 | -10118.2% | +12500.6 |
| Q4 FY2025 | Dec 31, 2025 | -14057.1% | −1046.0 |
| Q3 FY2025 | Sep 30, 2025 | -9411.5% | +3414.2 |
| Q2 FY2025 | Jun 30, 2025 | -10584.0% | −3196.0 |
| Q1 FY2025 | Mar 31, 2025 | -22618.8% | −8283.8 |
| Q4 FY2024 | Dec 31, 2024 | -13011.1% | +8533.5 |
| Q3 FY2024 | Sep 30, 2024 | -12825.7% | +4906.9 |
| Q2 FY2024 | Jun 30, 2024 | -7388.0% | +2533.4 |
| Q1 FY2024 | Mar 31, 2024 | -14335.0% | +16717.4 |
| Q4 FY2023 | Dec 31, 2023 | -21544.6% | −5894.6 |
| Q3 FY2023 | Sep 30, 2023 | -17732.6% | −8181.1 |
| Q4 FY2022 | Dec 31, 2022 | -9921.4% | +4968.6 |
| Q3 FY2022 | Sep 30, 2022 | -31052.4% | −19146.3 |
| Q2 FY2022 | Jun 30, 2022 | -15650.0% | +515.2 |
| Q1 FY2022 | Mar 31, 2022 | -9551.5% | +3823.5 |
| Q4 FY2021 | Dec 31, 2021 | -14890.0% | −2628.1 |
| Q3 FY2021 | Sep 30, 2021 | -11906.1% | −2586.6 |
| Q2 FY2021 | Jun 30, 2021 | -16165.2% | −7815.2 |
| Q1 FY2021 | Mar 31, 2021 | -13375.0% | −5986.1 |
| Q4 FY2020 | Dec 31, 2020 | -12261.9% | −6085.9 |
| Q3 FY2020 | Sep 30, 2020 | -9319.4% | −4065.3 |
| Q2 FY2020 | Jun 30, 2020 | -8350.0% | +2767.2 |
| Q1 FY2020 | Mar 31, 2020 | -7388.9% | −6280.1 |
| Q4 FY2019 | Dec 31, 2019 | -6176.0% | +1818.7 |
| Q3 FY2019 | Sep 30, 2019 | -5254.1% | +4524.7 |
| Q2 FY2019 | Jun 30, 2019 | -11117.2% | −6528.0 |
| Q4 FY2018 | Dec 31, 2018 | -1108.8% | +4477.3 |
| Q3 FY2018 | Sep 30, 2018 | -7994.7% | −5048.1 |
| Q2 FY2018 | Jun 30, 2018 | -9778.8% | −8497.1 |
| Q1 FY2018 | Mar 31, 2018 | -4589.3% | −731.0 |
| Q4 FY2017 | Dec 31, 2017 | -5586.0% | +19945.3 |
| Q3 FY2017 | Sep 30, 2017 | -2946.7% | +11717.0 |
| Q2 FY2017 | Jun 30, 2017 | -1281.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -3858.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -25531.3% | – |
| Q3 FY2016 | Sep 30, 2016 | -14663.6% | – |
See a number that looks wrong?